Investors who lost money in Iovance Biotherapeutics, Inc. (IOVA) have opportunity to lead…

Investors who have suffered losses in connection with their investments in the Iovance Biotherapeutics, Inc. (IOVA) are being given the opportunity to participate in an ongoing securities fraud lawsuit. The lead plaintiff deadline for this lawsuit is July 14, 2025.

The lawsuit revolves around allegations of securities fraud related to IOVA. Investors who purchased or otherwise acquired IOVA securities between May 9, 2019, and March 11, 2021, inclusive, may be eligible to participate in the lawsuit. The allegations suggest that the company made misleading statements or failed to disclose information that caused its stock price to be artificially inflated.

One of the main issues in the lawsuit pertains to IOVA’s lead product candidate, LN-145. The lawsuit alleges that IOVA exaggerated the efficacy of LN-145 for treating cervical cancer stem cells, which led to its stock price being artificially inflated. When the truth of the matter was revealed, the stock price plummeted, resulting in financial losses for investors.

Furthermore, the lawsuit claims that IOVA touted LN-145 as a revolutionary cancer treatment without disclosing significant adverse events associated with the drug. This alleged misleading information also contributed to the inflation of IOVA’s stock price.

Investors who believe they have been impacted by these actions and suffered financial losses as a result are encouraged to participate in the lawsuit. By joining the ongoing securities fraud lawsuit, investors may be able to recover some or all of the losses incurred due to the alleged misconduct of IOVA.

It is crucial for investors to take action before the lead plaintiff deadline on July 14, 2025, in order to be considered for participation in the lawsuit. Seeking legal guidance and representation to understand the specifics of the case and determine the best course of action is recommended for investors who believe they have been affected by the alleged securities fraud.

In conclusion, the ongoing securities fraud lawsuit against IOVA presents an opportunity for investors who have suffered losses in connection with the company’s alleged misconduct. By participating in the lawsuit before the lead plaintiff deadline, investors may have the chance to seek financial recovery for the losses incurred due to the misleading statements and alleged inflation of IOVA’s stock price.